Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth (Status and Outlook) 2022-2028
- LP 4912441
- 103 Pages
- March 2022
- Medical Devices
The United States NTRK Fusion Gene Positive Advanced Solid Tumor market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global NTRK Fusion Gene Positive Advanced Solid Tumor market, reaching US$ million by the year 2028. As for the Europe NTRK Fusion Gene Positive Advanced Solid Tumor landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main NTRK Fusion Gene Positive Advanced Solid Tumor players cover Bayer, Teva Pharmaceuticals, Empire Genomics, and SeraCare Life Sciences, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of NTRK Fusion Gene Positive Advanced Solid Tumor market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Therapeutics
Diagnostics
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospitals and Clinics
Cancer Centers
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Bayer
Teva Pharmaceuticals
Empire Genomics
SeraCare Life Sciences
F. Hoffmann-La Roche
NeoGenomics Laboratories
Glaxosmithkline
OncoDNA
Merck & Co.
Daiichi Sankyo
S Deciphera Pharmaceuticals
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2017-2028
2.1.2 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Segment by Type
2.2.1 Therapeutics
2.2.2 Diagnostics
2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
2.3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2022)
2.4 NTRK Fusion Gene Positive Advanced Solid Tumor Segment by Application
2.4.1 Hospitals and Clinics
2.4.2 Cancer Centers
2.4.3 Others
2.5 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
2.5.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2022)
3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Player
3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Players
3.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Players (2020-2022)
3.1.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Players (2020-2022)
3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NTRK Fusion Gene Positive Advanced Solid Tumor by Regions
4.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Regions (2017-2022)
4.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2017-2022)
4.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2017-2022)
4.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2017-2022)
4.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2017-2022)
5 Americas
5.1 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022)
5.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
5.3 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2017-2022)
6.2 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
6.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor by Country (2017-2022)
7.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
7.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor by Region (2017-2022)
8.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022)
8.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Regions (2023-2028)
10.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Regions (2023-2028)
10.1.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.1.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.1.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.1.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
10.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Country (2023-2028)
10.2.1 United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.2.2 Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.2.3 Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.2.4 Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2023-2028)
10.3.1 China NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.3.2 Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.3.3 Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.3.4 Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.3.5 India NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.3.6 Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Country (2023-2028)
10.4.1 Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.4.2 France NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.4.3 UK NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.4.4 Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.4.5 Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2023-2028)
10.5.1 Egypt NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.5.2 South Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.5.3 Israel NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.5.4 Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.5.5 GCC Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
10.6 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Type (2023-2028)
10.7 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.1.3 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Information
11.2.2 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.2.3 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Teva Pharmaceuticals Main Business Overview
11.2.5 Teva Pharmaceuticals Latest Developments
11.3 Empire Genomics
11.3.1 Empire Genomics Company Information
11.3.2 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.3.3 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Empire Genomics Main Business Overview
11.3.5 Empire Genomics Latest Developments
11.4 SeraCare Life Sciences
11.4.1 SeraCare Life Sciences Company Information
11.4.2 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.4.3 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 SeraCare Life Sciences Main Business Overview
11.4.5 SeraCare Life Sciences Latest Developments
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Information
11.5.2 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.5.3 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 F. Hoffmann-La Roche Main Business Overview
11.5.5 F. Hoffmann-La Roche Latest Developments
11.6 NeoGenomics Laboratories
11.6.1 NeoGenomics Laboratories Company Information
11.6.2 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.6.3 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 NeoGenomics Laboratories Main Business Overview
11.6.5 NeoGenomics Laboratories Latest Developments
11.7 Glaxosmithkline
11.7.1 Glaxosmithkline Company Information
11.7.2 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.7.3 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Glaxosmithkline Main Business Overview
11.7.5 Glaxosmithkline Latest Developments
11.8 OncoDNA
11.8.1 OncoDNA Company Information
11.8.2 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.8.3 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 OncoDNA Main Business Overview
11.8.5 OncoDNA Latest Developments
11.9 Merck & Co.
11.9.1 Merck & Co. Company Information
11.9.2 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.9.3 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Merck & Co. Main Business Overview
11.9.5 Merck & Co. Latest Developments
11.10 Daiichi Sankyo
11.10.1 Daiichi Sankyo Company Information
11.10.2 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.10.3 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Daiichi Sankyo Main Business Overview
11.10.5 Daiichi Sankyo Latest Developments
11.11 S Deciphera Pharmaceuticals
11.11.1 S Deciphera Pharmaceuticals Company Information
11.11.2 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
11.11.3 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 S Deciphera Pharmaceuticals Main Business Overview
11.11.5 S Deciphera Pharmaceuticals Latest Developments
12 Research Findings and Conclusion
Table 1. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Therapeutics
Table 3. Major Players of Diagnostics
Table 4. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2022)
Table 7. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2022)
Table 10. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Player (2020-2022)
Table 12. NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Products Offered
Table 13. NTRK Fusion Gene Positive Advanced Solid Tumor Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Regions (2017-2022)
Table 18. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Country (2017-2022)
Table 20. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2022)
Table 22. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2022)
Table 24. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region (2017-2022)
Table 26. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2022)
Table 28. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2022)
Table 30. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Country (2017-2022)
Table 32. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2022)
Table 34. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of NTRK Fusion Gene Positive Advanced Solid Tumor
Table 43. Key Market Challenges & Risks of NTRK Fusion Gene Positive Advanced Solid Tumor
Table 44. Key Industry Trends of NTRK Fusion Gene Positive Advanced Solid Tumor
Table 45. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share Forecast by Application (2023-2028)
Table 51. Bayer Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 52. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 53. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Bayer Main Business
Table 55. Bayer Latest Developments
Table 56. Teva Pharmaceuticals Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 57. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 58. Teva Pharmaceuticals Main Business
Table 59. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Teva Pharmaceuticals Latest Developments
Table 61. Empire Genomics Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 62. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 63. Empire Genomics Main Business
Table 64. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. Empire Genomics Latest Developments
Table 66. SeraCare Life Sciences Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 67. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 68. SeraCare Life Sciences Main Business
Table 69. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. SeraCare Life Sciences Latest Developments
Table 71. F. Hoffmann-La Roche Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 72. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 73. F. Hoffmann-La Roche Main Business
Table 74. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. F. Hoffmann-La Roche Latest Developments
Table 76. NeoGenomics Laboratories Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 77. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 78. NeoGenomics Laboratories Main Business
Table 79. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 80. NeoGenomics Laboratories Latest Developments
Table 81. Glaxosmithkline Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 82. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 83. Glaxosmithkline Main Business
Table 84. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 85. Glaxosmithkline Latest Developments
Table 86. OncoDNA Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 87. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 88. OncoDNA Main Business
Table 89. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 90. OncoDNA Latest Developments
Table 91. Merck & Co. Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 92. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 93. Merck & Co. Main Business
Table 94. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 95. Merck & Co. Latest Developments
Table 96. Daiichi Sankyo Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 97. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 98. Daiichi Sankyo Main Business
Table 99. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 100. Daiichi Sankyo Latest Developments
Table 101. S Deciphera Pharmaceuticals Details, Company Type, NTRK Fusion Gene Positive Advanced Solid Tumor Area Served and Its Competitors
Table 102. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
Table 103. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 104. S Deciphera Pharmaceuticals Main Business
Table 105. S Deciphera Pharmaceuticals Latest Developments
List of Figures
Figure 1. NTRK Fusion Gene Positive Advanced Solid Tumor Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type in 2021
Figure 7. NTRK Fusion Gene Positive Advanced Solid Tumor in Hospitals and Clinics
Figure 8. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market: Hospitals and Clinics (2017-2022) & ($ Millions)
Figure 9. NTRK Fusion Gene Positive Advanced Solid Tumor in Cancer Centers
Figure 10. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market: Cancer Centers (2017-2022) & ($ Millions)
Figure 11. NTRK Fusion Gene Positive Advanced Solid Tumor in Others
Figure 12. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market: Others (2017-2022) & ($ Millions)
Figure 13. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application in 2021
Figure 14. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Player in 2021
Figure 15. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Regions (2017-2022)
Figure 16. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2017-2022 ($ Millions)
Figure 17. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2017-2022 ($ Millions)
Figure 18. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2017-2022 ($ Millions)
Figure 20. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Value Market Share by Country in 2021
Figure 21. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Consumption Market Share by Type in 2021
Figure 22. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application in 2021
Figure 23. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region in 2021
Figure 28. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application in 2021
Figure 29. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 33. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Country in 2021
Figure 36. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type in 2021
Figure 37. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application in 2021
Figure 38. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 39. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application in 2021
Figure 46. Egypt NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 52. APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 53. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 55. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 56. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 57. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 58. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 59. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 60. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 61. Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 63. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 64. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 65. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 66. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 67. UK NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 68. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 69. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 70. Spain NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 71. Egypt NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 72. South Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 73. Israel NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 74. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Figure 75. GCC Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2023-2028 ($ Millions)
Similar Reports
This report provides an overview of the French molecular diagnostic testing market, including test volume, and sales forecasts by Application, 2019-2023, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
This report provides an overview of the German molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
This report provides an overview of the Italian molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
